Salivary gland cancers: Biology and molecular targets for therapy

Current Oncology Reports

Volumn 14, Issue 2, 2012, Pages 166-174

  Bell, Diana ^a   Hanna, E Y ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenoid cystic carcinoma; Fusion oncogenes; Head and neck cancers; Molecular targeted therapy; Mucoepidermoid carcinoma; Salivary cancers

Indexed keywords

AXITINIB; BORTEZOMIB; CETUXIMAB; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; GROWTH FACTOR; IMATINIB; LAPATINIB; MAML2 PROTEIN; MECT1 PROTEIN; NUCLEAR FACTOR I; ONCOPROTEIN; PROTEIN MYB; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; MECT1 MAML2 FUSION PROTEIN, HUMAN; MECT1-MAML2 FUSION PROTEIN, HUMAN; MYB NFIB FUSION PROTEIN, HUMAN; MYB-NFIB FUSION PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE REGULATION; CHROMOSOME TRANSLOCATION; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 19; CHROMOSOME TRANSLOCATION 6; CHROMOSOME TRANSLOCATION 9; CPG ISLAND; DIAGNOSTIC VALUE; DRUG TARGETING; ENZYME INHIBITION; FUSION GENE; GENE MUTATION; HISTOGENESIS; HUMAN; MOLECULARLY TARGETED THERAPY; MORPHOGENESIS; MULTIPLE CYCLE TREATMENT; ONCOGENE; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN METHYLATION; SALIVARY GLAND CANCER; SIGNAL TRANSDUCTION; GENE TRANSLOCATION; GENETICS; METHODOLOGY; PATHOLOGY; SALIVARY GLAND TUMOR;

ANTINEOPLASTIC AGENTS; CARCINOMA, ADENOID CYSTIC; CARCINOMA, MUCOEPIDERMOID; HUMANS; MOLECULAR TARGETED THERAPY; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; SALIVARY GLAND NEOPLASMS; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84860852345     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-012-0220-5     Document Type: Article

References (59)

1. Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2, 807 patients. Head Neck Surg. 1986;8 (3): 177-84.
2. Regezi JA, Batsakis JG. Histogenesis of salivary gland neoplasms. Otolaryngol Clin North Am. 1977;10 (2): 297-307. (Pubitemid 8110315)
3. Fordice J, Kershaw C, El-Naggar A, Goepfert H. Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg. 1999;125 (2): 149-52. (Pubitemid 29085262)
4. Batsakis JG, Regezi JA, Luna MA, El-Naggar A. Histogenesis of salivary gland neoplasms: a postulate with prognostic implications. J Laryngol Otol. 1989;103 (10): 939-44. (Pubitemid 19251855)
5. Brenner JC, Chinnaiyan AM. Translocations in epithelial cancers. Biochim Biophys Acta. 2009;1796 (2): 201-15.
6. Stenman G, Andersson MK, Andren Y. New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer. Cell Cycle. 9 (15): 2986-95.
7. Stenman G. Fusion oncogenes and tumor type specificity-insights from salivary gland tumors. Semin Cancer Biol. 2005;15 (3): 224-35.
8. Nordkvist A, Gustafsson H, Juberg-Ode M, Stenman G. Recurrent rearrangements of 11q14-22 in mucoepidermoid carcinoma. Cancer Genet Cytogenet. 1994;74 (2): 77-83. (Pubitemid 24208871)
9. Persson M, Andren Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A. 2009;106 (44): 18740-4.
10. Antonescu CR, Katabi N, Zhang L, et al. EWSR1-ATF1 fusion is a novel and consistent finding in hyalinizing clear-cell carcinoma of salivary gland. Gene Chromosome Canc. 2011;50 (7): 559-70.
11. Skalova A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010;34 (5): 599-608.
12. Seethala RR, Dacic S, Cieply K, Kelly LM, Nikiforova MN. A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas. Am J Surg Pathol. 34 (8): 1106-21
13. Tonon G, Modi S, Wu L, et al. (11;19) (q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet. 2003;33 (2): 208-13. (Pubitemid 36177076)
14. Iourgenko V, Zhang W, Mickanin C, et al. Identification of a family of cAMP response element-binding protein coactivators by genome-scale functional analysis in mammalian cells. Proc Natl Acad Sci U S A. 2003;100 (21): 12147-52. (Pubitemid 37271529)
15. Anzick SL, Chen WD, Park Y, et al. Unfavorable prognosis of CRTC1-MAML2 positive mucoepidermoid tumors with CDKN2A deletions. Gene Chromosome Canc. 2010;49 (1): 59-69.
16. Komiya T, Park Y, Modi S, Coxon AB, Oh H, Kaye FJ. Sustained expression of Mect1-Maml2 is essential for tumor cell growth in salivary gland cancers carrying the t (11;19) translocation. Oncogene. 2006;25 (45): 6128-32. (Pubitemid 44562411)
17. Jaskoll T, Htet K, Abichaker G, Kaye FJ, Melnick M. CRTC1 expression during normal and abnormal salivary gland development supports a precursor cell origin for mucoepidermoid cancer. Gene Expr Patterns. 2011;11 (1-2): 57-63.
18. Behboudi A, Enlund F, Winnes M, et al. Molecular classification of mucoepidermoid carcinomas-prognostic significance of the MECT1-MAML2 fusion oncogene. Gene Chromosome Canc. 2006;45 (5): 470-81.
19. Tirado Y, Williams MD, Hanna EY, Kaye FJ, Batsakis JG, El-Naggar AK. CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands andWarthin's tumors: implications for histogenesis and biologic behavior. Gene Chromosome Canc. 2007;46 (7): 708-15. (Pubitemid 46802338)
20. Fehr A, Roser K, Heidorn K, Hallas C, Loning T, Bullerdiek J. A new type of MAML2 fusion in mucoepidermoid carcinoma. Gene Chromosome Canc. 2008;47 (3): 203-6. (Pubitemid 351162851)
21. Nakayama T, Miyabe S, Okabe M, et al. Clinicopathological significance of the CRTC3-MAML2 fusion transcript in mucoepidermoid carcinoma. Mod Pathol. 2009;22 (12): 1575-81.
22. Seethala RR. An update on grading of salivary gland carcinomas. Head Neck Pathol. 2009;3 (1): 69-77.
23. Mitani Y, Li J, Rao PH, et al. Comprehensive analysis of the MYBNFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance. Clin Cancer Res. 16 (19): 4722-31.
24. El-Naggar AK, Dinh M, Tucker SL, Swanson D, Steck K, Vielh P. Numerical chromosomal changes in DNA hypodiploid solid tumors: restricted loss and gain of certain chromosomes. Cytometry. 1999;37 (2): 107-12. (Pubitemid 29463479)
25. Bell D, Roberts D, Kies M, Rao P, Weber RS, El-Naggar AK. Cell type-dependent biomarker expression in adenoid cystic carcinoma: biologic and therapeutic implications. Cancer. 2010;116 (24): 5749-56. This study showed c-kit expression to be limited to the ductal epithelial cells, while EGFR was found mainly in the myoepithelial cells of the majority of tubular and cribriform pattern ACCs. In solid ACC, c-kit was uniformly positive whereas EGFR was consistently negative. C-Kit expression was associated with worse 3-year outcome and EGFR expression correlated significantly with a better 3-year outcome. These findings underscore the importance of myoepithelial and ductal cell localization of biomarkers in the biological and therapeutic stratification of patients with this entity.
26. Bell A, Bell D, Weber RS, El-Naggar AK. CpG island methylation profiling in human salivary gland adenoid cystic carcinoma. Cancer. 2011.
27. Mayor R, Casadome L, Azuara D, et al. Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of disease. Br J Cancer. 2009;100 (10): 1534-9.
28. Wu X, Rauch TA, Zhong X, et al. CpG island hypermethylation in human astrocytomas. Cancer Res. 2010;70 (7): 2718-27.
29. Lasa A, Carnicer MJ, Aventin A, et al. MEIS 1 expression is downregulated through promoter hypermethylation in AML1- ETO acute myeloid leukemias. Leukemia. 2004;18 (7): 1231-7. (Pubitemid 39023133)
30. Zangenberg M, Grubach L, Aggerholm A, et al. The combined expression of HOXA4 and MEIS1 is an independent prognostic factor in patients with AML. Eur J Haematol. 2009;83 (5): 439-48.
31. Cottrell S, Jung K, Kristiansen G, et al. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J Urol. 2007;177 (5): 1753-8. (Pubitemid 46560648)
32. Venza I, Visalli M, Tripodo B, et al. FOXE1 is a target for aberrant methylation in cutaneous squamous cell carcinoma. Br J Dermatol. 2010;162 (5): 1093-7.
33. Dunwell T, Hesson L, Rauch TA, et al. A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers. Mol Canc. 2010;9: 44.
34. Bell D, Bell A, Roberts D, Weber RS, El-Naggar AK. Developmental transcription factor EN1-a novel biomarker in human salivary gland adenoid cystic carcinoma*. Cancer. 2011.
35. Durr ML, Mydlarz WK, Shao C, et al. Quantitative methylation profiles for multiple tumor suppressor gene promoters in salivary gland tumors. PLoS One. 2010;5 (5): e10828.
36. Edwards PC, Bhuiya T, Kelsch RD. C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95 (5): 586-93. (Pubitemid 36886706)
37. Holst VA, Marshall CE, Moskaluk CA, Frierson Jr HF. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol. 1999;12 (10): 956-60. (Pubitemid 29485269)
38. Mino M, Pilch BZ, Faquin WC. Expression of KIT (CD117) in neoplasms of the head and neck: an ancillary marker for adenoid cystic carcinoma. Mod Pathol. 2003;16 (12): 1224-31. (Pubitemid 38018604)
39. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002;20 (6): 1692-703. (Pubitemid 34260552)
40. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med. 2003;348 (11): 994-1004. (Pubitemid 36302244)
41. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial. Lancet. 2004;364 (9440): 1127-34. (Pubitemid 39296599)
42. Izquierdo MA, Van der Valk P, Van Ark-Otte J, et al. Differential expression of the c-kit proto-oncogene in germ cell tumours. J Pathol. 1995;177 (3): 253-8.
43. Rao PH, Roberts D, Zhao YJ, et al. Deletion of 1p32-p36 is the most frequent genetic change and poor prognostic marker in adenoid cystic carcinoma of the salivary glands. Clin Cancer Res. 2008;14 (16): 5181-7.
44. Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol. 2005;23 (3): 585-90. (Pubitemid 46224236)
45. Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol. 2007;43 (1): 33-6. (Pubitemid 46162246)
46. Nguyen LH, Black MJ, Hier M, Chauvin P, Rochon L. HER2/neu and Ki-67 as prognostic indicators in mucoepidermoid carcinoma of salivary glands. J Otolaryngol. 2003;32 (5): 328-31. (Pubitemid 38175965)
47. Skalova A, Starek I, Vanecek T, et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology. 2003;42 (4): 348-56. (Pubitemid 36459812)
48. Dagrada GP, Negri T, Tamborini E, Pierotti MA, Pilotti S. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence insitu hybridization and immunohistochemistry. Histopathology. 2004;44 (3): 301-2. (Pubitemid 38406627)
49. Prat A, Parera M, Reyes V, et al. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck. 2008;30 (5): 680-3. (Pubitemid 351656111)
50. Glisson B, Colevas AD, Haddad R, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res. 2004;10 (3): 944-6. (Pubitemid 38198894)
51. Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003;39 (7): 724-7. (Pubitemid 36930120)
52. Shadaba A, Gaze MN, Grant HR. The response of adenoid cystic carcinoma to tamoxifen. J Laryngol Otol. 1997;111 (12): 1186-9. (Pubitemid 28040657)
53. Vattemi E, Graiff C, Sava T, Pedersini R, Caldara A, Mandara M. Systemic therapies for recurrent and/or metastatic salivary gland cancers. Expert Rev Anticancer Ther. 2008;8 (3): 393-402. (Pubitemid 351836287)
54. Milano A, Longo F, Basile M, Iaffaioli RV, Caponigro F. Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy. Oral Oncol. 2007;43 (8): 729-34. (Pubitemid 47259451)
55. Locati LD, Quattrone P, Bossi P, Marchiano AV, Cantu G, Licitra L. A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann Oncol. 2003;14 (8): 1327-8. (Pubitemid 37039062)
56. van der Hulst RW, van Krieken JH, van der Kwast TH, et al. Partial remission of parotid gland carcinoma after goserelin. Lancet. 1994;344 (8925): 817. (Pubitemid 24283970)
57. Agulnik M, Cohen EW, Cohen RB, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol. 2007;25 (25): 3978-84. (Pubitemid 47477277)
58. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005;23 (24): 5474-83.
59. Argiris A, Cohen E, Karrison T, et al. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Canc Biol Ther. 2006;5 (7): 766-70. (Pubitemid 44775131)